Merck, nearing completion of $1B Gardasil manufacturing push, eyes 2023 to double production⁠—again

URLhttps://www.fiercepharma.com/pharma/merck-amid-1b-
SourceFierce Pharma
Date Published04/22/2022
Author NameFraiser Kansteiner
Mentions specific company case(s) of reshoring, kept from offshoring, or transplantYes

Additional Reshoring Information:

Company/Division name Merck & Co., Inc.
Type of work Manufacturing
Reshoring category:Reshoring
Total number of jobs (added or to be added):150
What product(s) and/or service(s) were outsourced domestically?Manufacturing
Year reshoring announced:2022
Capital investment ($):1000
City reshored to:Elkton
State(s) reshored to:VA
If relevant, work nearshored to:-
Industry(ies):Chemicals
Product(s) reshoredhuman papillomavirus (HPV) vaccine
What non-domestic negative factors made offshoring less attractive?Supply chain interruption risk/Natural disaster risk/Political instability
Find Reshoring Articles